Data from Eiger BioPharmaceuticals, Inc.’s Phase III TOGETHER study of peginterferon lambda in non-hospitalized COVID-19 patients at high risk of progressing to severe disease or death showed the subcutaneous drug as highly effective in preventing hospitalization and death.
The company plans to speak with the US Food and Drug Administration and submit for emergency use authorization, as well as seek authorization with other regulatory agencies, “as soon as possible
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?